

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7609519

|   |   |                       |
|---|---|-----------------------|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                          |                       |
| <b>NATURE OF CONVEYANCE:</b>  | ASSIGNMENT                              |                       |
| <b>CONVEYING PARTY DATA</b>   |   |                       |
|   | <b>Name</b>                             | <b>Execution Date</b> |
|   | GALARY, INC.                            | 04/25/2022            |
| <b>RECEIVING PARTY DATA</b>   |   |                       |
| <b>Name:</b>  | GALVANIZE THERAPEUTICS, INC.            |                       |
| <b>Street Address:</b>  | 1531 INDUSTRIAL ROAD                    |                       |
| <b>City:</b>  | SAN CARLOS                              |                       |
| <b>State/Country:</b>   | CALIFORNIA                              |                       |
| <b>Postal Code:</b>   | 94070                                   |                       |
| <b>PROPERTY NUMBERS Total: 2</b>  |   |                       |
| <b>Property Type</b>  | <b>Number</b>                           |                       |
| <b>Application Number:</b>  | 16381745                                |                       |
| <b>Application Number:</b>  | 16898320                                |                       |
| <b>CORRESPONDENCE DATA</b>  |   |                       |
| <b>Fax Number:</b>  |   |                       |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |   |                       |
| <b>Email:</b>   | jroeder@wsgr.com, patentdocket@wsgr.com |                       |
| <b>Correspondent Name:</b>  | WILSON SONSINI GOODRICH & ROSATI        |                       |
| <b>Address Line 1:</b>  | 650 PAGE MILL ROAD                      |                       |
| <b>Address Line 4:</b>  | PALO ALTO, CALIFORNIA 94304             |                       |
| <b>ATTORNEY DOCKET NUMBER:</b>  | 54150-703302 AND 303                    |                       |
| <b>NAME OF SUBMITTER:</b>   | JOY A. ROEDER                           |                       |
| <b>SIGNATURE:</b>   | /Joy A. Roeder/                         |                       |
| <b>DATE SIGNED:</b>   | 10/25/2022                              |                       |
| <b>Total Attachments: 4</b>   |   |                       |
| source=Galary_to_Galvanize_Assignment#page1.tif   |   |                       |
| source=Galary_to_Galvanize_Assignment#page2.tif   |   |                       |
| source=Galary_to_Galvanize_Assignment#page3.tif   |   |                       |
| source=Galary_to_Galvanize_Assignment#page4.tif   |   |                       |

**CORPORATE TO CORPORATE PATENT ASSIGNMENT**Docket Number 58880-700

Galary, Inc., having a place of business at 1531 Industrial Road, San Carlos, CA, 94070, (the "Assignor"), hereby desires to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Galvanize Therapeutics, Inc., a Delaware Corporation, having a place of business at 1531 Industrial Road, San Carlos, CA, 94070, (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor has obtained the entire right, title and interest in and to certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

**SEE EXHIBIT A ATTACHED HERETO**

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

3. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.

4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, and assigns, and shall be binding upon said Assignor and its assigns.

5. Said Assignor hereby warrants, represents and covenants that Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

6. Said Assignor hereby requests that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors and assigns.

7. This instrument will be interpreted and construed in accordance with the laws of the [Name of State / Commonwealth / Country], without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below:

AGREED TO BY ASSIGNOR: Galary, Inc.

04/25/22

Date: \_\_\_\_\_

Signature:  \_\_\_\_\_

Name: Jonathan Waldstreicher  
Title: CEO

RECEIVED AND AGREED TO BY ASSIGNEE: Galvanize Therapeutics, Inc.

04/25/22

Date: \_\_\_\_\_

Signature:  \_\_\_\_\_

Name: Jonathan Waldstreicher  
Title: CEO

# EXHIBIT A

| Case Number | Subcase | Application Number | Filing Date | Patent Number | Issue Date  |
|-------------|---------|--------------------|-------------|---------------|-------------|
| 58880-703   | 101     | 62/355,164         | 27-Jun-2016 |               |             |
| 58880-703   | 102     | 62/489,753         | 25-Apr-2017 |               |             |
| 58880-703   | 301     | 16/227,796         | 20-Dec-2018 |               |             |
| 58880-703   | 302     | 16/381,745         | 11-Apr-2019 | 10,702,337    | 07-Jul-2020 |
| 58880-703   | 303     | 16/898,320         | 10-Jun-2020 | 10,939,958    | 09-Mar-2021 |
| 58880-703   | 601     | PCT/US2017/039527  | 27-Jun-2017 |               |             |
| 58880-704   | 101     | 62/610,430         | 26-Dec-2017 |               |             |
| 58880-704   | 301     | 16/914,072         | 26-Jun-2020 |               |             |
| 58880-704   | 302     | 17/214,688         | 26-Mar-2021 |               |             |
| 58880-704   | 601     | PCT/US2018/067501  | 26-Dec-2018 |               |             |
| 58880-705   | 101     | 62/693,622         | 03-Jul-2018 |               |             |
| 58880-705   | 301     | 16/914,200         | 26-Jun-2020 |               |             |
| 58880-705   | 601     | PCT/US2018/067504  | 26-Dec-2018 |               |             |
| 58880-706   | 101     | 62/835,846         | 18-Apr-2019 |               |             |
| 58880-706   | 301     | 17/502,640         | 15-Oct-2021 |               |             |
| 58880-706   | 601     | PCT/US2020/028844  | 17-Apr-2020 |               |             |
| 58880-707   | 101     | 62/874,605         | 16-Jul-2019 |               |             |
| 58880-707   | 301     | 17/575,500         | 13-Jan-2022 |               |             |
| 58880-707   | 601     | PCT/US2020/042260  | 16-Jul-2020 |               |             |
| 58880-708   | 101     | 62/902,004         | 18-Sep-2019 |               |             |
| 58880-708   | 102     | 63/076,536         | 10-Sep-2020 |               |             |
| 58880-708   | 103     | 63/241,241         | 07-Sep-2021 |               |             |
| 58880-709   | 101     | 62/949,633         | 18-Dec-2019 |               |             |
| 58880-709   | 301     | 17/466,871         | 03-Sep-2021 |               |             |
| 58880-709   | 601     | PCT/US2020/066205  | 18-Dec-2020 |               |             |
| 58880-710   | 101     | 62/994,620         | 25-Mar-2020 |               |             |
| 58880-710   | 501     | 17/212,833         | 25-Mar-2021 |               |             |
| 58880-711   | 101     | 63/000,275         | 26-Mar-2020 |               |             |
| 58880-712   | 101     | 63/007,233         | 08-Apr-2020 |               |             |
| 58880-712   | 102     | 63/078,784         | 15-Sep-2020 |               |             |
| 58880-712   | 601     | PCT/US2021/026221  | 07-Apr-2021 |               |             |
| 58880-713   | 101     | 63/061,091         | 04-Aug-2020 |               |             |
| 58880-713   | 601     | PCT/US2021/044469  | 04-Aug-2021 |               |             |
| 58880-714   | 101     | 63/061,114         | 04-Aug-2020 |               |             |
| 58880-715   | 101     | 63/083,644         | 25-Sep-2020 |               |             |
| 58880-716   | 101     | 63/159,331         | 10-Mar-2021 |               |             |
| 58880-716   | 601     | PCT/US2022/019719  | 10-Mar-2022 |               |             |
| 58880-717   | 101     | 63/166,145         | 25-Mar-2021 |               |             |
| 58880-717   | 601     | PCT/US2022/021888  | 25-Mar-2022 |               |             |
| 58880-718   | 101     | 63/178,174         | 22-Apr-2021 |               |             |
| 58880-719   | 101     | 63/189,358         | 17-May-2021 |               |             |
| 58880-720   | 101     | 63/209,319         | 10-Jun-2021 |               |             |
| 58880-721   | 101     | 63/209,335         | 10-Jun-2021 |               |             |
| 58880-721   | 601     | PCT/US2022/015217  | 04-Feb-2022 |               |             |
| 58880-723   | 101     | 63/246,239         | 20-Sep-2021 |               |             |
| 58880-723   | 102     | 63/322,319         | 22-Mar-2022 |               |             |
| 58880-724   | 101     | 63/282,521         | 23-Nov-2021 |               |             |
| 58880-725   | 101     | 63/290,529         | 16-Dec-2021 |               |             |

This audit trail was created during the document signature process and holds details of parties involved, including email address of signer(s), device IPs, signature timestamp and more. It serves as a digital certificate and can be used as a legal evidence.

|                        |                                   |
|------------------------|-----------------------------------|
| DOCUMENT               | Galaxy to Galvanize 58880-700.pdf |
| INITIATOR EMAIL        | lynne@galatherapeutics.com        |
| INITIATOR REFERENCE ID | d0e582a12e314d1f5a2b28424ad4f0c12 |

| DOCUMENT NAME       | FINGERPRINT         | REFERENCE ID        | VERIFICATION LINK               |
|---------------------|---------------------|---------------------|---------------------------------|
| Galaxy to Galvanize | 3abd089e545446e298  | bd6a5f67bed845d8ab5 | <a href="#">Click to verify</a> |
| 58880-700.pdf       | a8e8a08ba0d96664fa9 | d04dc646247ee       |                                 |
|                     | 7a64a31ea75ec948d68 |                     |                                 |
|                     | 6244df5b            |                     |                                 |



LEGAL

Electronic signature are legally binding and admissible in a court of law in accordance with the ESIGN Act in United States and eIDAS in the European Union. Most of the other countries around the world as well have adopted an electronic signature law or have recognized electronic signatures for business or personal transactions.



SECURE

This document was securely processed using 256 bit SSL encryption technology for the communication channels between your device and the secure servers hosted at Amazon Web Services, which is ISO 27001 compliant.



TRUST

Signeasy is trusted and used by thousands of companies and millions of people in over 150 countries.



Learn more at <https://signeasy.com>



Signature request initiated for:

**Jon@GalaTherapeutics.com (Jonathan Waldstreicher)**

Initiated on: 2022-04-21 21:09:53 UTC

IP: 107.214.150.85



**Signed By jon@galatherapeutics.com (Jonathan Waldstreicher)**

Signed on: 2022-04-25 12:42:22 UTC

IP: 108.53.211.253



**Signature request completed.**

Completed on: 2022-04-25 12:42:24 UTC

IP: 108.53.211.253